Amerikanische Gesellschaft für Hirudotherapie

Breast Reconstruction Flap Salvage

FDA-cleared application: venous decompression of compromised DIEP, TRAM, and latissimus dorsi flaps in post-mastectomy reconstruction.

Tier A — FDA-cleared indicationFDA-zugelassene Medizinprodukt-IndikationLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Yes — FDA-cleared under K040187 (June 21, 2004) for medicinal leech application to relieve venous congestion in microsurgical reconstructive procedures, including breast reconstruction flaps.
Welche Evidenz existiert?
This is an FDA-cleared use. The largest published hospital series (Nguyen 2012, n=154) reports that about 78 percent of congested DIEP flaps were saved when leech therapy was added to surgical re-exploration. Major U.S. cancer centers (MD Anderson, Memorial Sloan Kettering, Mayo) include leech availability in their post-operative protocols. Leeches do not replace surgery — if the issue is an artery problem or a fixable surgical clot, the surgical team must address that first.
Hauptrisiken
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Need for blood transfusion (about 1 in 3 patients) from cumulative blood loss over the treatment course
  • Aeromonas hydrophila infection (your team starts an antibiotic such as ciprofloxacin before the first leech)
  • Loss of the flap despite treatment if the underlying artery problem cannot be fixed
  • Allergic reaction to leech saliva (uncommon)
  • Visible bite-mark scarring on the reconstructed breast that may fade but may not disappear entirely
  • Longer hospital stay and emotional stress from a complication after an already long surgery
Wer dies nicht in Betracht ziehen sollte
  • Patients on warfarin, apixaban, rivaroxaban, dabigatran, or heparin
  • Patients with hemophilia or another inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL) before therapy
  • Patients with active bloodstream infection or sepsis
  • Patients allergic to ciprofloxacin and other antibiotics covering Aeromonas
  • Patients whose flap has completely died (no salvage is possible — surgical removal is needed)
  • Patients whose flap problem is an artery issue (this requires surgical revision, not leeches)
Was Sie Ihren Kliniker fragen sollten
  • Is this an artery problem, a vein problem, or both? Leeches only help with vein problems.
  • Should I be taken back to the operating room before or instead of starting leech therapy?
  • Which antibiotic will I get for Aeromonas prevention, and for how long?
  • How often will my blood count be checked, and at what level would you transfuse?
  • How will the bite scars look once everything heals, and is there anything that helps them fade?
  • If the flap fails despite leeches, what are my options — a new flap from a different site, an implant, or no reconstruction?
  • Will my breast cancer follow-up care be affected by this complication or by the transfusions?
Wann dringende medizinische Versorgung suchen
  • Bleeding from any bite site soaking through more than one dressing per hour, or bleeding lasting more than 24 hours after the leech detaches
  • Increasing redness, warmth, swelling, or pus around the flap or bite sites
  • Fever above 38.0 C / 100.4 F, chills, or feeling suddenly unwell
  • Flap turning darker, colder, or harder despite leech therapy
  • Hives, swelling of the face or tongue, or any breathing difficulty

Was dies NICHT bedeutet

  • It does not mean the flap is guaranteed to survive — about 20 to 40 percent of severely congested flaps are still lost, especially when the artery is the real problem.
  • It does not mean leeches replace surgical re-exploration — for early problems (less than 6 hours after surgery) the team will usually take you back to the operating room first.
  • It does not mean home use is safe — this is hospital therapy with antibiotics and blood-count monitoring.
  • It does not affect your cancer outcome — leech therapy is for the reconstruction, not the cancer treatment.

Clinical Profile

Category
surgical reconstruction
ICD-10
T86.821, T87.41, N64.89, Z90.13
Safety tier
high

Evidence Summary

Free flap breast reconstruction (DIEP, TRAM, SIEA, PAP, latissimus) has a venous compromise rate of 3-7%. Early identification (within hours) and prompt leech application can support flap salvage in a substantial fraction of cases that would otherwise progress toward total flap loss. Evidence is drawn from mixed-flap experience rather than breast-specific trials: a 2012 systematic review of 277 reported clinical cases of leech therapy across plastic and reconstructive surgery found an overall success (salvage) rate of about 78%, while a 2012 retrospective series of 39 patients with venous congestion found that among 27 regional and free flaps roughly one-third were fully salvaged, one-third partially salvaged, and one-third lost. Routine institutional protocols at major reconstructive centers include leech availability in the postoperative pathway. Leech therapy does not replace surgical re-exploration for arterial issues or for early venous compromise where revision of the anastomosis is feasible.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Nguyen MQ et al. (2012), n=39 · PMID 22473683 · ASH analysis →
  2. Knobloch K et al. (2007)0 · PMID 17497605 · ASH analysis →
  3. Whitaker IS et al. (2012), n=277 · PMID 22407551 · ASH analysis →
Sample sizes of key trials for Breast Reconstruction Flap SalvageNguyen MQ et al. 201239Whitaker IS et al. 2012277
Participants per key trial (n). Larger trials generally carry more statistical weight; case series with unspecified counts are omitted.
Study-design composition of the evidence base for Breast Reconstruction Flap Salvage3studies
  • Cohort: 1 (33%)
  • Systematic Review: 2 (67%)
Composition of the cited evidence base by study design, from strongest (meta-analysis, systematic review) to weakest (case report). A base weighted toward RCTs and reviews is more reliable.

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Total flap necrosis (non-salvageable; proceed to debridement)
  • Arterial insufficiency (must address surgically before leeching)

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Breast Reconstruction Flap Salvage — Hirudotherapy Evidence | ASH